TOMAO, SILVERIO
 Distribuzione geografica
Continente #
NA - Nord America 7.670
EU - Europa 2.664
AS - Asia 795
SA - Sud America 54
AF - Africa 35
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 11.224
Nazione #
US - Stati Uniti d'America 7.592
IT - Italia 944
SE - Svezia 598
IN - India 433
CN - Cina 290
UA - Ucraina 271
FI - Finlandia 221
DE - Germania 149
IE - Irlanda 119
CA - Canada 77
BE - Belgio 70
GB - Regno Unito 69
BG - Bulgaria 51
FR - Francia 47
AR - Argentina 42
RO - Romania 41
SG - Singapore 39
AT - Austria 30
TG - Togo 21
NL - Olanda 15
IR - Iran 12
RU - Federazione Russa 10
CH - Svizzera 9
ZA - Sudafrica 9
CL - Cile 7
HK - Hong Kong 7
BR - Brasile 5
EE - Estonia 4
EU - Europa 3
JP - Giappone 3
MK - Macedonia 3
PH - Filippine 3
PT - Portogallo 3
TR - Turchia 3
AU - Australia 2
DK - Danimarca 2
EG - Egitto 2
HR - Croazia 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GR - Grecia 1
IL - Israele 1
KZ - Kazakistan 1
MA - Marocco 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PL - Polonia 1
RS - Serbia 1
SC - Seychelles 1
VA - Santa Sede (Città del Vaticano) 1
Totale 11.224
Città #
Fairfield 1.303
Ashburn 675
Woodbridge 625
Chandler 610
Seattle 507
Houston 467
Wilmington 426
Cambridge 412
Rome 352
Ann Arbor 279
Princeton 233
San Paolo di Civitate 226
Beijing 198
Plano 183
Lawrence 158
Dublin 118
Millbury 112
Boston 100
San Diego 100
Jacksonville 96
Brussels 65
Dearborn 62
Helsinki 55
Andover 54
Sofia 51
Norwalk 45
New York 43
Bremen 42
Federal 41
Fremont 32
Milan 32
Ottawa 31
Toronto 31
Vienna 28
Boardman 23
Falls Church 21
Grafing 21
Lomé 21
Phoenix 19
Redwood City 17
Des Moines 15
London 15
Sacramento 14
Hefei 13
Nanjing 13
San Mateo 12
Pune 11
Washington 11
North York 10
Kunming 9
Buffalo 8
Leawood 8
Padova 8
Cappelle sul Tavo 7
Guangzhou 7
Hong Kong 7
Southend 7
Jinan 6
Muizenberg 6
Trumbull 5
Birmingham 4
Ercolano 4
Hyderabad 4
Indiana 4
Kashan 4
Laurel 4
Montréal 4
Mumbai 4
Palermo 4
Romainville 4
Shenyang 4
Tallinn 4
Waanrode 4
Zhengzhou 4
Bangalore 3
Bari 3
Chengdu 3
Dallas 3
Florence 3
Genoa 3
Glasgow 3
Groningen 3
Istanbul 3
Marcallo con Casone 3
Melegnano 3
Paris 3
Patna 3
Redmond 3
Schio 3
Simi Valley 3
Torino 3
Vicenza 3
Viterbo 3
Zanjan 3
Augusta 2
Bengaluru 2
Berlin 2
Bisceglie 2
Bovisio-Masciago 2
Brooklyn 2
Totale 8.234
Nome #
Angiogenic factors as prognostic markers in neuroendocrine neoplasms 158
Breast metastasis and lung large-cell neuroendocrine carcinoma: first clinical observation 117
Analysis of p53 expression in precancerous and malignant gastric mucosa 117
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: a real-world experience 115
Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families 114
Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC) 112
223Ra-dichloride therapy in an elderly bone metastatic castration-resistant prostate cancer patient: a case report presentation and comparison with existing literature 109
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 103
Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens 100
Prevalence of human papillomavirus, cytomegalovirus, and Epstein-Barr virus in the cervix of healthy women 99
Malignant transformation of well-differentiated papillary mesothelioma 13 years after the diagnosis: a case report 98
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: the EverExt study 96
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 93
Continuous, low-dose capecitabine for patients with recurrent colorectal cancer 88
INfluenza vaccine indication during therapy with Immune checkpoint inhibitors: a transversal challenge. the INVIDIa study 87
Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer 85
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab 85
Adjuvant therapy for early uterine high-grade leiomyosarcoma 83
Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study. 81
Breast cancer risk after ovarian stimulation for In vitro fertilization 80
The role of BMI and age in chemotherapy-induced amenorrhea (CIA) in premenopausal breast cancer (PBC) patients treated with adjuvant FEC100 with or without docetaxel (D) 80
Radium‑223 in patients with metastatic castration‑resistant prostate cancer: efficacy and safety in clinical practice 80
Circulating tumor cells in right-and left-sided colorectal cancer 80
Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era 80
M8Concomitant versus sequential Fotemustine and Bevacizumab in recurrent malignant gliomas: treatment response and survival outcomes in a retrospective analysis 79
Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software. 79
Acrocyanosis, digital ischemia and acronecrosis as first manifestations of endometrial adenocarcinoma: case presentation and literature review 79
Current approach in the treatment of hepatocellular carcinoma. 78
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment 78
G-CSF related bone pain (BP) and Bv8/PK2 expression: Is there a link in breast cancer (BC) patients (pts) treated with FEC100 adjuvant chemotherapy (CT)? 77
Bevacizumab in glioblastomas: lights and shadows 77
Current role and safety profile of aromatase inhibitors in early breast cancer 76
Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy 76
Toxicity of targeted therapy in non-small-cell lung cancer management 75
Niraparib in ovarian cancer. results to date and clinical potential 75
A 68-year-old Caucasian man presenting with urinary bladder lymphoepithelioma: a case report 75
Adjuvant chemotherapy in completely resected gastric cancer: A Randomized phase III trial conducted by GOIRC 74
Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: relief from immunosuppression is associated with clinical response 74
The synchronous occurrence of squamous cell carcinoma and gastrointestinal stromal tumor (GIST) at esophageal site 73
Triple-negative breast cancer: investigating potential molecular therapeutic target 73
Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey. 73
Multimodal treatment for local recurrent malignant gliomas: resurgery and/or reirradiation followed by chemotherapy 73
Early clear cell “sugar” lung cancer management: a case report and a brief literature review 73
Triple negative breast cancer: new perspectives for targeted therapies 72
BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models 72
Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. 71
Synchronous primary neoplasms of the bladder, skin and breast in a male patient: A case report 71
Angiogenesis and antiangiogenic agents in cervical cancer 70
Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families 70
Association between diverticulosis and colonic neoplastic lesions in individuals with a positive faecal immunochemical test 70
17) Follow-up of intestinal metaplasia in the stomach: When, how and why. 69
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study 69
Immunologic treatments for precancerous lesions and uterine cervical cancer 69
Therapeutic approach in glioblastoma multiforme with primitive neuroectodermal tumor components: case report and review of the literature 68
The 5-Ws of immunotherapy in head and neck cancer 68
Relationship between b-catenin expression and epithelial cell proliferation in gastric mucosa with intestinal metaplasia. 67
Eradication Therapy for Helicobacter pylori in Patients With Gastric MALT Lymphoma: A Pooled Data Analysis 67
Subcutaneous metastases from colon cancer: A case report 67
Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting 67
Primary Low-grade and High-grade Gastric MALT-lymphoma Presentation 67
Correlation between fertility drugs use and malignant melanoma incidence: the state of the art 67
Paclitaxel and Alisertib in recurrent ovarian cancer 66
Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis 65
Fertility drugs and breast cancer risk 65
Circulating tumor cells in high-risk nonmetastatic colorectal cancer 63
Quality of life effects of ovarian suppression in the suppression of ovarian function trial 63
Onset of hepatocellular carcinoma in a non-cirrhotic patient affected with haemochromatosis. 62
Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients 62
Fertility drugs, reproductive strategies and ovarian cancer risk 62
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome 62
Ovarian function, reproduction and strategies for fertility preservation after breast cancer 62
S47A retrospective analysis to evaluted the off-label use Bevacizumab in recurrent malignant gliomas 61
K-ras mutations and cetuximab in colorectal cancer 60
Bone metastases from bladder perivascular epithelioid cell tumor - An unusual localization of a rare tumor: A case report 60
Progesterone therapy in endometrial cancer 60
La presentazione clinico-endoscopica del linfoma gastrico. 60
Chemotherapy-induced nausea and vomiting in Italian cancer centers: Results of CINVDAY, a prospective, multicenter study 60
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach 59
Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy 59
Gastric epithelial cell proliferation in patients with liver cirrhosis 59
Role of diet in endometrial cancer patients 58
Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice. 58
Cerebral metastases in patients with left atrial myxoma 58
Investigating molecular profiles of ovarian cancer: an update on cancer stem cells. 58
Gastric epithelial cell proliferation in patients with liver cirrhosis 57
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 56
Single-center experience with pegfilgrastim (P) and lenograstim (L) in nonmetastatic breast cancer (NMBC) patients (pts) during adjuvant FEC100 or sequential FEC100 plus DOCETAXEL100 (D100) 56
Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: Basic knowledge and therapeutic possibilities for an innovative approach 56
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 56
Current status of bevacizumab in advanced ovarian cancer 56
Eradication therapy in Helicobacter pylori-negative, gastric low-grade mucosa-associated lymphoid tissue lymphoma patients: a systematic review. 55
DETERMINATION OF PAH-DNA ADDUCTS IN LUNG TISSUE OF CANCER PATIENTS 54
Expression of er, pgr, her-2, and ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy 54
Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer. 54
Positron Emission Tomography (PET) radiotracers in oncology - utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC) 53
Anticancer treatment and fertility effects. Literature review 53
Nonpegylated liposomal doxorubicin (nPLD) in neoadjuvant treatment of local advanced breast cancer (LABC) patients (pts) 53
Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM) 53
A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer 52
Effect of epoetin on survival in patients with breast cancer 52
Totale 7.290
Categoria #
all - tutte 30.056
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.056


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.046 0 0 0 0 0 0 0 0 28 208 431 379
2019/20202.838 374 79 52 149 287 335 341 349 323 278 159 112
2020/20211.091 150 114 69 82 40 134 29 87 98 196 77 15
2021/20222.338 50 117 185 143 297 60 49 246 170 156 440 425
2022/20232.734 508 640 168 234 258 231 70 153 269 43 126 34
2023/2024970 91 186 74 100 152 219 36 101 11 0 0 0
Totale 11.791